Article
Hematology
Juan-Carlos Hernandez-Boluda, Arturo Pereira, Nicolaus Kroeger, Jan J. Cornelissen, Juergen Finke, Dietrich Beelen, Moniek de Witte, Keith Wilson, Uwe Platzbecker, Henrik Sengeloev, Didier Blaise, Hermann Einsele, Katja Sockel, William Krueger, Stig Lenhoff, Adriano Salaroli, Hans Martin, Valentin Garcia-Gutierrez, Vicenzo Pavone, Alberto Alvarez-Larran, Jose-Maria Raya, Nienke Zinger, Luuk Gras, Patrick Hayden, Tomasz Czerw, Donal P. McLornan, Ibrahim Yakoub-Agha
Summary: Allogeneic hematopoietic cell transplantation (allo-HCT) may improve survival rates for older myelofibrosis patients, but comes with a higher excess mortality rate compared to non-transplant approaches. Busulfan-based conditioning is associated with lower mortality, while recipient CMV+/donor CMV- combination and JAK2 mutated genotype predict higher mortality.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Patrick J. Hayden, Dirk-Jan Eikema, Liesbeth C. de Wreede, Linda Koster, Nicolaus Kroger, Hermann Einsele, Monique Minnema, Alida Dominietto, Michael Potter, Jacob Passweg, Arancha Bermudez, Stephanie Nguyen-quoc, Uwe Platzbecker, Johanna Tischer, Fabio Ciceri, Joan Hendrik Veelken, Per Ljungman, Nicolaas Schaap, Edouard Forcade, Angelo Michele Carella, Virginie Gandemer, William Arcese, Adrian Bloor, Attilio Olivieri, Laure Vincent, Meral Beksac, Stefan Schonland, Ibrahim Yakoub-Agha
Summary: For patients with relapsed multiple myeloma, receiving a second allo-HCT from a HLA-identical sibling donor for both transplants is associated with higher overall survival rates. Additionally, an interval of more than 2 years between transplants is associated with superior 5-year survival rates.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Aniko Sijs-Szabo, Avinash G. Dinmohamed, Jurjen Versluis, Bronno van der Holt, Mar Bellido, Mette D. Hazenberg, Michel van Gelder, Nicolaas P. M. Schaap, Ellen Meijer, Lotte E. van der Wagen, Constantijn J. M. Halkes, Anita W. Rijneveld, Jan J. Cornelissen
Summary: In this retrospective study, RIC-alloHSCT was compared with MAC-alloHSCT in older adult patients with acute lymphoblastic leukemia. The results showed that RIC-alloHSCT had lower nonrelapse mortality but a significantly higher relapse rate compared to MAC-alloHSCT. These findings suggest that MAC-alloHSCT may be a more effective consolidation therapy for reducing relapse.
Review
Cell Biology
Nicola Polverelli, Mirko Farina, Mariella D'Adda, Enrico Damiani, Luigi Grazioli, Alessandro Leoni, Michele Malagola, Simona Bernardi, Domenico Russo
Summary: Moving from indication to transplantation is a critical process in managing myelofibrosis patients. This review focuses on identifying suitable candidates for transplantation using disease-specific prognostic scores and evaluating their eligibility based on performance, comorbidity, and other combined tools. The review also discusses the importance of pre-transplant management in achieving successful engraftment and reducing non-relapse mortality and relapse incidence. Topics such as managing splenomegaly, constitutional symptoms, cytopenias, iron overload, and choosing the right donor and conditioning regimens are comprehensively explored. The aim of this review is to provide practical guidance for managing myelofibrosis patients who may undergo allo-HCT.
Review
Hematology
Nico Gagelmann, Nicolaus Kroeger
Summary: Allogeneic hematopoietic stem-cell transplantation is a potentially curative therapy for various hematologic diseases, with the success dependent on the conditioning regimen used pre-transplant. Studies have shown a correlation between conditioning regimen intensity and toxicity, prompting research to focus on reducing toxicity and increasing safety for broader populations. Individual factors and risks play a crucial role in selecting the appropriate intensity of the conditioning regimen.
Review
Health Care Sciences & Services
Heather R. Wolfe, Mitchell E. Horwitz, Lindsay A. M. Rein
Summary: Primary myelofibrosis is a BCR-ABL1 negative myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells. Allogenic hematopoietic stem cell transplantation may provide a safe and effective curative option for a broader range of primary myelofibrosis patients in the future.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Siddharth Kunte, Lisa Rybicki, Auro Viswabandya, Roni Tamari, Asad Bashey, Alla Keyzner, Madiha Iqbal, Michael R. Grunwald, Bhagirathbhai Dholaria, Hany Elmariah, Michael Ozga, Anurag Singh, Sameem Abedin, Amy E. DeZern, Richard J. Jones, Vikas Gupta, Aaron T. Gerds, Tania Jain
Summary: The study demonstrates that haplo-BMT with PTCy is effective in treating myelofibrosis, but splenomegaly >= 22 cm and bone marrow grafts are associated with an increased risk of relapse.
Article
Biophysics
Mitja Nabergoj, Katya Mauff, Marie Robin, Nicolaus Kroeger, Emanuele Angelucci, Xavier Poire, Jakob Passweg, Aleksandar Radujkovic, Uwe Platzbecker, Stephen Robinson, Alessandro Rambaldi, Soren Lykke Petersen, Fridrich Stoelzel, Matthias Stelljes, Fabio Ciceri, Jiri Mayer, Marco Ladetto, Liesebeth C. de Wreede, Linda Koster, Patrick J. Hayden, Tomasz Czerw, Juan Carlos Hernandez-Boluda, Donal McLornan, Yves Chalandon, Ibrahim Yakoub-Agha
Summary: This study retrospectively analyzed 216 patients with MF undergoing a second allo-HCT, finding a 42% three-year overall survival rate and a 39% three-year relapse-free survival rate. The incidence of acute and chronic GVHD was relatively high, with a 14% graft failure rate at 1 year.
BONE MARROW TRANSPLANTATION
(2021)
Review
Immunology
Andrea Bacigalupo, Idanna Innocenti, Elena Rossi, Federica Sora, Eugenio Galli, Francesco Autore, Elisabetta Metafuni, Patrizia Chiusolo, Sabrina Giammarco, Luca Laurenti, Giulia Benintende, Simona Sica, Valerio De Stefano
Summary: This review provides an update on the current status of allogeneic HSCT for patients with myelofibrosis, covering indications, prognostic scoring systems, transplant outcome prediction, transplant platform choice, and complications.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Juan Carlos Hernandez-Boluda, Arturo Pereira, Nicolaus Kroeger, Dietrich Beelen, Marie Robin, Martin Bornhaeuser, Emanuele Angelucci, Antonin Vitek, Igor Wolfgang Blau, Riitta Niittyvuopio, Juergen Finke, Jan J. Cornelissen, Jakob Passweg, Peter Dreger, Eefke Petersen, Lothar Kanz, Jaime Sanz, Tsila Zuckerman, Nienke Zinger, Simona Iacobelli, Patrick Hayden, Tomasz Czerw, Donal McLornan, Ibrahim Yakoub-Agha
Summary: This study aimed to evaluate survival determinants in myelofibrosis patients undergoing allo-HCT and describe factors predicting post-HCT complications. Factors associated with increased mortality included age, Karnofsky Performance Status, graft failure, aGVHD, and disease progression/relapse. Risk of aGVHD and relapse incidence varied with donor type and conditioning regimen, with GVHD having a complex impact on relapse and survival.
Review
Oncology
Donal P. McLornan, Juan Carlos Hernandez Boluda, Tomasz Czerw, Nicholas Cross, H. Joachim Deeg, Marcus Ditschkowski, Mufaddal T. Moonim, Nicola Polverelli, Marie Robin, Mahmoud Aljurf, Eibhlin Conneally, Patrick Hayden, Ibrahim Yakoub-Agha
Summary: Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative approach in myelofibrosis, but relapse rates are still significant. EBMT proposed new definitions and management strategies for graft failure, poor graft function and relapse, as well as recommended systematic monitoring and testing methods to increase accuracy in reporting.
Article
Biophysics
Nobuhiko Imahashi, Seitaro Terakura, Eisei Kondo, Koji Kato, Sung-Won Kim, Akihito Shinohara, Mizuki Watanabe, Takahiro Fukuda, Naoyuki Uchida, Hikaru Kobayashi, Jun Ishikawa, Keisuke Kataoka, Souichi Shiratori, Takashi Ikeda, Ken-ichi Matsuoka, Shuro Yoshida, Tadakazu Kondo, Takafumi Kimura, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda
Summary: The study showed that UCB transplantation with optimal conditioning and GVHD prophylaxis had better outcomes compared to MRD and MUD transplantation, suggesting it is a highly effective treatment for mature lymphoid malignancies. This indicates that UCB transplantation might be preferred over MRD or MUD transplantation in certain settings.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).
Article
Medicine, Research & Experimental
Erika S. Varady, L. Angel Ayala, Pauline U. Nguyen, Vanessa M. Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A. Greilach, Craig M. Walsh, Matthew A. Inlay
Summary: Donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation increases HSC engraftment and reduces the severity and incidence of graft-versus-host disease (GvHD) in allogeneic hosts.
EMBO MOLECULAR MEDICINE
(2023)
Letter
Hematology
Sebastian Stasik, Jan M. Middeke, Michael Kramer, Christoph Roellig, Alwin Kraemer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Bruemmendorf, Ralph Naumann, Bjorn Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schaefer-Eckart, Christoph Schliemann, Stefan Krause, Regina Herbst, Mathias Haenel, Norbert Frickhofen, Richard Noppeney, Ulrich Kaiser, Claudia D. Baldus, Martin Kaufmann, Zdenek Racil, Uwe Platzbecker, Wolfgang E. Berdel, Jiri Mayer, Hubert Serve, Carsten Mueller-Tidow, Gerhard Ehninger, Martin Bornhaeuser, Johannes Schetelig, Christian Thiede
Article
Acoustics
Alexandra Wilczynski, Christian Goerg, Nina Timmesfeld, Annette Ramaswamy, Andreas Neubauer, Andreas Burchert, Corinna Trenker
JOURNAL OF ULTRASOUND IN MEDICINE
(2020)
Letter
Hematology
Christian Michel, Elisabeth K. M. Mack, Christopher-Nils Mais, Lea V. Fritz, Ying Wang, Lutz B. Jehn, Sonja K. Huehn, Clara Simon, Sabrina Inselmann, Andre Marquardt, Jennifer Kremer, Ellen Wollmer, Kristina Sohlbach, Andreas Neubauer, Cornelia A. Brendel, Claudia Haferlach, Gert Bange, Andreas Burchert
Article
Hematology
Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C. P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosee, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C. P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth
AMERICAN JOURNAL OF HEMATOLOGY
(2020)
Article
Oncology
Ruediger Hehlmann, Astghik Voskanyan, Michael Lauseker, Markus Pfirrmann, Lida Kalmanti, Sebastien Rinaldetti, Katharina Kohlbrenner, Claudia Haferlach, Brigitte Schlegelberger, Alice Fabarius, Wolfgang Seifarth, Birgit Spiess, Patrick Wuchter, Stefan Krause, Hans-Jochem Kolb, Andreas Neubauer, Dieter K. Hossfeld, Christoph Nerl, Alois Gratwohl, Gabriela M. Baerlocher, Andreas Burchert, Tim H. Bruemmendorf, Joerg Hasford, Andreas Hochhaus, Susanne Saussele, Michele Baccarani
Letter
Oncology
Andreas Burchert, Stephan K. Metzelder, Andreas Neubauer, Michael Wittenberg, Carmen Schade-Brittinger
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Patrizia Malkomes, Ilaria Lunger, Elsie Oppermann, Khalil Abou-El-Ardat, Thomas Oellerich, Stefan Guenther, Can Canbulat, Sabrina Bothur, Frank Schnuetgen, Weijia Yu, Susanne Wingert, Nadine Haetscher, Claudia Catapano, Marina S. Dietz, Mike Heilemann, Hans-Michael Kvasnicka, Katharina Holzer, Hubert Serve, Wolf Otto Bechstein, Michael A. Rieger
Summary: TGM2 plays a crucial role in colorectal cancer, with its transamidation activity being essential for promoting cell survival. By binding to the tumor suppressor gene p53, TGM2 inactivates it, affecting apoptosis induction in cancer cells.
Article
Oncology
Lioba Schoenfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schaefer, Thomas Schenk, Christian Fabisch, Tim H. Bruemmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus, Thomas Ernst
Summary: Gene mutations independent of BCR::ABL1, especially in epigenetic modifier genes, are common in newly diagnosed patients with chronic myeloid leukemia in chronic phase. Specifically, ASXL1 mutations have been found to be the most commonly affected. These mutations are associated with less favorable molecular response to nilotinib treatment, and patients carrying ASXL1 mutations are typically younger and more frequently classified as high risk, suggesting a central role of clonal evolution associated with ASXL1 mutations in CML pathogenesis.
Article
Biophysics
Juergen Finke, Claudia Schmoor, Matthias Stelljes, Andreas Burchert, Peter Dreger, Ute Hegenbart, Eva-Maria Wagner-Drouet, Martin Bornhaeuser, Kristina Sohlbach, Natalie Schub, Christian Reicherts, Guido Kobbe, Bertram Glass, Hartmut Bertz, Olga Grishina
Summary: This study aimed to investigate the efficacy of a second allogeneic HCT using Thiotepa, Fludarabine, and Treosulfan (TFT) as conditioning therapy in patients with AML relapse > 6 months after the first allogeneic HCT. The results showed that this approach is feasible and has a high anti-leukemic efficacy, but relapse rates and non-relapse mortality remain a challenge.
BONE MARROW TRANSPLANTATION
(2022)
Meeting Abstract
Medicine, Research & Experimental
Veronika Weyerer, Nadina Ortiz-Bruchle, Melanie Demes, Oliver Schildgen, Johannes Haybaeck, Gabriela Westphal, Philip Sander, Thomas Mairinger, Wolfgang Goering, Thomas Aigner, Udo Siebolts, Annika Moske, Achim Battmann, Hans Michael Kvasnicka, Karsten Neumann, Lars Tharun, Daniela Nussbeck, Marianna Sciortino, Bruno Markl, Eva Wardelmann, Arndt Hartmann, Nikola Holtkamp
LABORATORY INVESTIGATION
(2021)
Meeting Abstract
Pathology
Veronika Weyerer, Nadina Ortiz-Bruechle, Melanie Demes, Oliver Schildgen, Johannes Haybaeck, Gabriela Westphal, Philip Sander, Thomas Mairinger, Wolfgang Goering, Thomas Aigner, Udo Siebolts, Annika Moske, Achim Battmann, Hans Michael Kvasnicka, Karsten Neumann, Lars Tharun, Daniela Nussbeck, Marianna Sciortino, Bruno Markl, Eva Wardelmann, Arndt Hartmann, Nikola Holtkamp
Article
Cardiac & Cardiovascular Systems
Mirjana Gotic, Miklos Egyed, Liana Gercheva, Krzysztof Warzocha, Hans Michael Kvasnicka, Heinrich Achenbach, Jingyang Wu
Summary: This study investigated the cardiac safety, efficacy, and tolerability of first-line treatment with anagrelide or hydroxyurea in high-risk ET patients. Both treatments controlled platelet counts without adverse cardiac effects, with majority of patients showing complete or partial responses. Long-term treatment with anagrelide did not affect cardiac function and confirmed the ET diagnosis through left ventricular ejection fraction assessment and central biopsy reading.
CARDIOVASCULAR TOXICOLOGY
(2021)
Article
Hematology
Konnie Hebeda, Ludmila Boudova, Christine Beham-Schmid, Attilio Orazi, Hans-Michael Kvasnicka, Umberto Gianelli, Alexandar Tzankov
Summary: The study summarized clinical, histopathological, and molecular features of 28 cases, indicating that accumulation of high-risk mutations in the trunk clone often leads to disease progression. Regular genetic testing may predict transformation and explain clinical progression. Histiocytic outgrowths are usually associated with a more aggressive course, and different clinical behaviors and risks may be context-dependent.
ANNALS OF HEMATOLOGY
(2021)
Meeting Abstract
Oncology
Thomas Ernst, Susanne Saussele, Andreas Burchert, Gabriela Maria Baerlocher, Tim Henrik Bruemmendorf, Paul Graf La Rosee, Dominik Heim, Stefan W. Krause, Philipp Le Coutre, Dietger Niederwieser, Thoralf Lange, Mathias Haenel, Frank Stegelmann, Kirsi Manz, Danny Himsel, Ruediger Hehlmann, Christian Fabisch, Markus Pfirrmann, Andreas Hochhaus
ONCOLOGY RESEARCH AND TREATMENT
(2020)
Article
Urology & Nephrology
Ivica Grgic, Andreas Burchert